Mar 12, 2025 5:08 pm EDT SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
Dec 18, 2024 8:00 am EST SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
Nov 6, 2024 4:30 pm EST SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oct 3, 2024 8:00 am EDT SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
Aug 27, 2024 8:00 am EDT SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
Aug 8, 2024 4:30 pm EDT SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 23, 2024 7:00 am EDT SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
May 8, 2024 4:30 pm EDT SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 30, 2024 4:05 pm EDT SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
